Trending...
- Colorado: Gov. Polis Announces Boards and Commissions Appointments
- Colorado Springs: Make your voice heard with CONO's Neighborhood University
- Colorado Springs: Podcast: Sharing our history
Download
(Photo: Business Wire)
NEW YORK & GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA's proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder. The National Center for Complimentary and Integrative Health (HCCIH-a division of the NIH) is providing funding for this trial which will be conducted at the NYU Grossman School of Medicine. (Clinical Trials.gov Identifier: NCT05571592)
More on Colorado Desk
The Principal Investigators for the trial are Naomi Simon, MD, MSc., Professor of Psychiatry and Director of Anxiety, Stress and Prolonged Grief Program at the NYU Grossman School of Medicine and Esther Blessing, MD, PhD, Assistant Professor of Psychiatry at NYU Grossman School of Medicine. This double-blind placebo-controlled trial will study Nantheia™ A1002N5S versus placebo over a 21-day treatment period with the primary outcome measures being the change in Trier Social Stress Test (TSST) induced Anxiety and impact on a neuroimaging biomarker.
"We are delighted to be moving forward with this important study to develop new evidence-based treatments for Social Anxiety Disorder, a distressing and under-addressed condition," said Dr Simon.
Dr. Blessing noted, "It is exciting to be moving forward with clinical trials that build upon promising preclinical results for CBD as a treatment for anxiety disorders."
"We are very pleased to again be working with Dr Simon and Dr Blessing on this important trial that could impact the lives of a large number of people," said Sohail R. Zaidi, ANANDA's CEO. "We look forward to further advancing applications for our investigational drug Nantheia A1002N5S in an indication with a significant unmet medical need."
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20220308005059%2Fen%2FANANDA-Scientific-and-NYU-Grossman-School-of-Medicine-Announce-First-Patient-Enrolled-in-the-Clinical-Trial-for-Opioid-Sparing-in-Participants-with-Radiculopathic-Pain&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Radiculopathic+Pain&index=8&md5=1583bdfab3e5aa6e72280a53ccffcde5), Anxiety and Opioid Use Disorder (Mt. Sinai (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20211019005004%2Fen%2FANANDA-Scientific%25E2%2580%2599s-Liquid-Structure%25E2%2584%25A2-Cannabidiol-CBD-to-Be-Clinically-Evaluated-for-Opioid-Use-Disorder&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Mt.+Sinai&index=9&md5=c7390692cddb3baae153188a12f6d0d6) and UCLA (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fananda-scientific-announces-first-patient-enrolled-in-the-clinical-trial-on-the-treatment-of-opioid-use-disorder-oud-301592512.html%3F%3Dprn&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=UCLA&index=10&md5=4423441644a84137a53b0c9ef1100ba5)). The company employs patented delivery technology, (licensed from Lyotropic Delivery Systems (LDS) Ltd (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.lds-biotech.com%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Lyotropic+Delivery+Systems+%28LDS%29+Ltd&index=11&md5=68fda5da92aba5885ea6a7e3c59451c7), in Jerusalem, Israel) to make cannabinoids and plant derived compounds bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium pharmaceutical products.
More on Colorado Desk
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Social Media Profiles
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
(Photo: Business Wire)
NEW YORK & GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA's proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder. The National Center for Complimentary and Integrative Health (HCCIH-a division of the NIH) is providing funding for this trial which will be conducted at the NYU Grossman School of Medicine. (Clinical Trials.gov Identifier: NCT05571592)
More on Colorado Desk
- Colorado Springs: Podcast: Focusing on Victims
- John Atencio Instagram – New Look and Feel
- Point-In-Time Count underway in Colorado Springs
- Colorado Springs: City Council seeks volunteers to serve on Boards, Commissions, and Committees
- Traveling Shamans Camp 2023 Open Registration
The Principal Investigators for the trial are Naomi Simon, MD, MSc., Professor of Psychiatry and Director of Anxiety, Stress and Prolonged Grief Program at the NYU Grossman School of Medicine and Esther Blessing, MD, PhD, Assistant Professor of Psychiatry at NYU Grossman School of Medicine. This double-blind placebo-controlled trial will study Nantheia™ A1002N5S versus placebo over a 21-day treatment period with the primary outcome measures being the change in Trier Social Stress Test (TSST) induced Anxiety and impact on a neuroimaging biomarker.
"We are delighted to be moving forward with this important study to develop new evidence-based treatments for Social Anxiety Disorder, a distressing and under-addressed condition," said Dr Simon.
Dr. Blessing noted, "It is exciting to be moving forward with clinical trials that build upon promising preclinical results for CBD as a treatment for anxiety disorders."
"We are very pleased to again be working with Dr Simon and Dr Blessing on this important trial that could impact the lives of a large number of people," said Sohail R. Zaidi, ANANDA's CEO. "We look forward to further advancing applications for our investigational drug Nantheia A1002N5S in an indication with a significant unmet medical need."
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20220308005059%2Fen%2FANANDA-Scientific-and-NYU-Grossman-School-of-Medicine-Announce-First-Patient-Enrolled-in-the-Clinical-Trial-for-Opioid-Sparing-in-Participants-with-Radiculopathic-Pain&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Radiculopathic+Pain&index=8&md5=1583bdfab3e5aa6e72280a53ccffcde5), Anxiety and Opioid Use Disorder (Mt. Sinai (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20211019005004%2Fen%2FANANDA-Scientific%25E2%2580%2599s-Liquid-Structure%25E2%2584%25A2-Cannabidiol-CBD-to-Be-Clinically-Evaluated-for-Opioid-Use-Disorder&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Mt.+Sinai&index=9&md5=c7390692cddb3baae153188a12f6d0d6) and UCLA (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fananda-scientific-announces-first-patient-enrolled-in-the-clinical-trial-on-the-treatment-of-opioid-use-disorder-oud-301592512.html%3F%3Dprn&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=UCLA&index=10&md5=4423441644a84137a53b0c9ef1100ba5)). The company employs patented delivery technology, (licensed from Lyotropic Delivery Systems (LDS) Ltd (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.lds-biotech.com%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Lyotropic+Delivery+Systems+%28LDS%29+Ltd&index=11&md5=68fda5da92aba5885ea6a7e3c59451c7), in Jerusalem, Israel) to make cannabinoids and plant derived compounds bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium pharmaceutical products.
More on Colorado Desk
- The Town Of Sun Village California Makes History As The First Black Tribal Township In North America
- Canvelle Announces New Line of Travel Sweatshirts & Sweatpants
- Flawless Torres ft. Diamonique x Sean Kingston Releases "Lets Go" on 1/27/23!
- Scott's Liquid Gold-Inc. Announces Sale of Wood and Floor Care Brands and Continued Pursuit of Strategic Alternatives
- We're In Paris Is Sidow Sobrino's Newly Released Song and Video
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Social Media Profiles
- Ananda Scientific (https://www.linkedin.com/company/ananda-scientific)
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
Filed Under: Business
0 Comments
Latest on Colorado Desk
- John Atencio To Introduce New Precious Silver & Gold Heart Designs In Time For Valentine's
- Promoting Statewide Access to Venture Funding: State Renews Partnership with Greater Colorado Venture Fund to Support Rural Businesses
- Colorado Springs: CSPD receives Grant to Improve Safety at Memorial Park
- Colorado Springs: Podcast: What is PPRTA?
- Yida Gao, Shima Capital Recognized for Prolific Deal Activity
- Strata Identity Raises $26M in Series B Financing to Extend Leadership in Multi-Cloud Identity Orchestration Market
- Quantum Metric Introduces Atlas to Empower Organizations to Expedite Digital Expertise USA - English Italia - Italiano Deutschland - Deutsch Deutschland - Deutsch USA - English
- Techstars, MCIT, RAED Ventures and Saudi National Bank Announce the Continuation of The Riyadh Techstars Accelerator
- Southern California Real Estate Agent Promotes Homes To MORE Buyers For MORE Money
- Can Massage Therapy Be an Effective Treatment for Long Haul COVID?
- Boulder SEO Marketing Founder Chris Raulf Teams up With the Globalization & Localization Association (GALA) To Present on Artificial Intelligence (AI)
- 2023 Colorado Water Plan Will Inspire Action to Build Stronger Water Future
- Liberty Energy Increases Share Repurchase Authorization to $500 Million and Announces Quarterly Cash Dividend
- John Atencio Valentine Gift with Purchase
- STS Capital Partners Announces Sean Friday as New Chief Executive Officer
- AVTECH Software Acquires Long Time United Kingdom Partner OPENXTRA
- Civitas Resources, Inc. Repurchases $300 Million of its Common Stock
- Colorado: Gov. Polis Announces Boards and Commissions Appointments
- Magnolia Road Launches New Pages on Cannabis Edibles, Cannabis Concentrates, and Cannabis Flower
- Colorado Springs: Make your voice heard with CONO's Neighborhood University